Sanofi has lost its bid to limit evidence from experts for Amgen in a patent dispute over a cholesterol-lowering antibody, with a judge dismissing concerns about Amgen having a majority of experts giving concurrent evidence. In an application filed at the beginning of the month, the French pharmaceutical company sought to bar Amgen from relying…
Indian generic drug maker Cipla has sued pharmaceutical giants Bristol-Myers Squibb and Pfizer alleging the patents behind their blockbuster deep vein thrombosis drug Eliquis are invalid.
The maker of Mother Energy drinks has failed to convince the High Court that it should weigh in on its long-running intellectual property spat with Vittoria Coffee, which ended in the removal of its ‘Motherland’ trade mark.
Buy now, pay later company Zip Co offered $4 million to settle a lawsuit by mortgage provider Firstmac alleging infringement of its ‘Zip’ trade mark which it ultimately defeated.
National Australia Bank is suing US company You Need A Budget, alleging the YNAB app, which helps users manage their finances, steps on its well-known trade mark and will confuse Australians.
Automotive electronics company Directed Electronics has lost its bid to revive copyright claims against a form business partner who it pursued as part of litigation over a scheme by two former employees to misappropriate its trade secrets through a secret side agreement with South Korean giant Hanhwa.
A solar cell patent at the heart of intellectual property litigation brought by South Korean technology giant Hanwha has been found invalid.
A 16-year battle between the federal government and drug maker Sanofi-Aventis over an allegedly unjustified court order that prevented the release of a generic version of blockbuster blood-thinner Plavix has gone to the High Court.
The maker of Mother energy drinks has won an appeal of an IP Australia decision, succeeding in its bid to prevent a Victoria-based company from registering Kangaroo Mother as a trade mark for beverages.
Novartis has lost its bid to have Pharmacor’s claim that its patent for a blood pressure drug is invalid decided ahead of a main trial where the Swiss pharmaceutical giant will allege the generic drug maker is threatening to infringe its patent.